TCM
ITOS

Tekla Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Tekla Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$606K Hold
45,735
– – 0.02% 137
2023
Q1 		$622K Buy
+45,735
New +$819K 0.02% 142
2022
Q3 		– Sell
-21,181
Closed -$436K – 178
2022
Q2 		$436K Sell
21,181
-21,181
-50% -$503K 0.02% 154
2022
Q1 		$1.36M Hold
42,362
– – 0.05% 135
2021
Q4 		$1.97M Hold
42,362
– – 0.06% 128
2021
Q3 		$1.14M Buy
+42,362
New +$1.11M 0.04% 150

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tekla Capital Management's ITOS Position: Q2 2023 in Review

Tekla Capital Management held its iTeos Therapeutics (ITOS) position steady in Q2 2023 at 45,735 shares worth $606K. The position accounts for 0.02% of the portfolio, ranked #137.

Tekla Capital Management first reported a position in ITOS in Q3 2021 and has held it in 6 quarters since. The position peaked at $1.97M in Q4 2021. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • Tekla Capital Management held 45,735 shares of iTeos Therapeutics worth $606K as of Q2 2023.
  • Tekla Capital Management left its iTeos Therapeutics share count unchanged in Q2 2023.
  • iTeos Therapeutics made up 0.02% of Tekla Capital Management's portfolio in Q2 2023, its #137 holding.
  • Tekla Capital Management first reported a position in iTeos Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • Tekla Capital Management's iTeos Therapeutics position peaked at $1.97M in Q4 2021.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.